The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the ...

The European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, US pharma giant Pfizer’s ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...